EGFR and non-small cell lung carcinoma: The advent of tyrosine kinase inhibitors (TKIs) has profoundly impacted the clinical outcomes of patients with NSCLC that exhibit EGFR-activating mutations, which is one of the most common contributing factors in NSCLC (114, 115).